Tags : Targeting

Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and

Tuba Khan January 25, 2021

Shots: Cardiff University will receive milestone payments that advance from the discovery collaboration into clinical development and royalty payments on sales of any products that reach the market. Ervaxx will fund this program Ervaxx gains an exclusive license to Cardiff University patents claiming T cells and TCRs reactive to cancer-specific antigens and has the right […]Read More

Clinical Trials

AstraZeneca Initiates P-IIb Study of ION449 (AZD8233) to Lower LDL-cholesterol

Tuba Khan December 1, 2020

Shots: The P-IIb study will evaluate three dose levels of ION449 (once a month, SC) vs PBO and will enroll ~108 patients aged 18-75yrs., who have LDL-C levels b/w 70-190 mg/dL and are receiving moderate/ high-intensity statin therapy The P-I study results demonstrated dose-dependent mean reductions in circulating plasma PCSK9 and LDL-C levels of >90% […]Read More

$Daiichi Sankyo Initiates P-I Study of DS-1055 for Relapsed/Refractory Advanced or Metastatic Solid Tumors$

Clinical Trials

Daiichi Sankyo Initiates P-I Study of DS-1055 for Relapsed/Refractory Advanced

Tuba Khan October 23, 2020

Shots: The P-I dose-escalation study will assess the safety, tolerability, and preliminary efficacy of DS-1055 in adult patients with r/r advanced or metastatic head and neck, gastric and esophageal cancers, and other tumor types The focus of the study is to determine the maximum tolerated dose and recommended dose of DS-1055 for further study and […]Read More

Biotech

Genentech Collaborates with Scenic Biotech to Develop Novel Therapies Targeting

Tuba Khan September 22, 2020

Shots: Scenic to receive ~$375M that includes up front, milestones along with royalties on sales of therapies emerges from the collaboration and will receive additional target fees for the therapies selected by Genentech The collaboration allows the Genentech to select multiple targets for further development with an option to extend the collaboration. Scenic will leverage […]Read More

Pharma

Junshi and Wigen Collaborate to Develop and Commercialize Four Therapies

Tuba Khan September 17, 2020

Shots: Wigen to transfer its 50% interest in four drugs WJ1024/WJ1075, WJ05129, APL1898, and WJ13404 to Junshi. Wigen to receive $5.3M up front, $64.3M as milestones, and 50% on the net profit of the therapies Junshi to get WW exclusive rights for the production and commercialization of these drugs and will be responsible for clinical […]Read More

Biotech

Kite and HiFiBiO Therapeutics Collaborate to Develop Antibodies Targeting Acute

Tuba Khan September 4, 2020

Shots: Kite enters into a two-year research collaboration and license agreement with HiFiBiO to discover novel targets and Abs against AML HiFiBiO will receive an up front and will utilize its technology platform to identify novel AML targets and anti-AML specific Abs to support Kite’s development of cell therapies Kite to get an exclusive option […]Read More

Pharma

Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic

Tuba Khan August 19, 2020

Shots: Evotec to receive $179M/ product as upfront, research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and commercialization of the therapies The companies will share responsibilities during drug discovery and pre-clinical development and will jointly identify and develop novel targets based on […]Read More

COVID-19 M&A

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic

Tuba Khan July 27, 2020

Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of Sorrento’s G-MAB Ab library and SmartPharm’s GET platform is expected […]Read More

Pharma

AbbVie Signs an Exclusive Research and Option to License Agreement

Tuba Khan June 26, 2020

Shots: Sosei to receive ~$32M as upfront and ~$377M as option fees, development, and commercial milestones along with royalties on global sales of therapies. AbbVie to get an option to expand the collaboration up to a total of four therapies that modulate GPCR Sosei will leverage its StaR technology and GPCR-focused SBDD capabilities and fund […]Read More

Pharma

Merck Collaborates with Yumanity to Accelerate the Development of Two

Tuba Khan June 25, 2020

Shots: Yumanity will receive $500M upfront and milestones along with royalties on net sales of therapies, in exchange Merck to get an exclusive right to two novels Yumanity’s pipeline programs for the treatment of ALS and FTLD The collaboration integrates Yumanity’s drug discovery platform with Merck’s development and commercialization expertise in neuroscience Yumanity and […]Read More

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US

Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes

Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids

Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar, aflibercept) in Korea

Biocon Biologics and Viatris Receive CHMP’s Positive Opinion for Abevmy (biosimilar, bevacizumab)

Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

Regeneron’s Ab Cocktail (casirivimab + imdevimab) Receives the CHMP’s Positive Opinion to Treat COVID-19

Kite’s Yescarta Receives the US FDA’s Approval for R/R Follicular Lymphoma

Roche to Withdraw Tecentriq Indication in Metastatic Bladder Cancer in the US

Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI

Gilead Presents Four-Year Data of Biktarvy for HIV-1 in Treatment-Naïve Adults at CROI 2021

Tags : Targeting

Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and

AstraZeneca Initiates P-IIb Study of ION449 (AZD8233) to Lower LDL-cholesterol

Daiichi Sankyo Initiates P-I Study of DS-1055 for Relapsed/Refractory Advanced

Genentech Collaborates with Scenic Biotech to Develop Novel Therapies Targeting

Junshi and Wigen Collaborate to Develop and Commercialize Four Therapies

Kite and HiFiBiO Therapeutics Collaborate to Develop Antibodies Targeting Acute

Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic

AbbVie Signs an Exclusive Research and Option to License Agreement

Merck Collaborates with Yumanity to Accelerate the Development of Two

Latest Posts

Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes

Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar, aflibercept) in Korea

ViewPoints Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10)

Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI

Tags : Targeting

Latest Posts

Categories

Related Topics